Fierce AI Week

While investment across the biopharma industry in R&D has been consistent or increased over the past 15 years, productivity has remained largely unchanged. Even with the projection that knowledge of medicine is doubling every 18 months, there must be better ways to understand biology and pathobiology and better ways to treat disease and manage healthcare.

Convergence, the result of the sharing of methods and ideas across multiple fields and industries, is the integration of insights and approaches from historically distinct scientific and technological disciplines. At AbbVie, our Convergence initiative seeks to create integrated R&D data and analytics capabilities that power data-driven insights – leading to better, faster decisions and therapies for patients. We are building a foundation for change, and setting out to double R&D productivity.

While hype alarms go off any time someone mentions Artificial Intelligence or ‘AI’, there are boundless opportunities to redefine AI – to engage it as the power of Automation and Insights – and drive value and impact in R&D. Tune in to this keynote to learn how AbbVie data scientists are helping our researchers scale the ladder of inference, how they are helping build foundations for growth and new capabilities, and how they are freeing up our people to perform higher value tasks. Ultimately guided by human empathy and experience, this will drive an increased ability to make a remarkable impact in the lives of patients.